medigraphic.com
ISSN 1405-8790 (Print)

2012, Number 3

<< Back Next >>

Rev Mex Med Fis Rehab 2012; 24 (3)

Correlation of estradiol, IGF-1, and sedentary bone densitometry in female mexican patients

Diez GMP, Ortiz RAC, Chávez ADD, Renán LS

Language: Spanish
References: 27
Page: 68-74
PDF size: 80.56 Kb.


ABSTRACT

Objective: To demonstrate the relationship between bone mineral density, estradiol-like growth factor (IGF-1) and physical inactivity in Mexican women over 45 with osteoporosis. Material and methods: We studied 41 patients with a mean age of 65.7 years (48-81 years). Were questioned metabolic disease history, physical inactivity and age at menopause. Underwent hip and spine bone mineral density and determination of serum estradiol and IGF-1. Results: IGF-1 significantly correlated with age (r = - .351, p = .045) lower concentrations of IGF-1 with increasing age; with standard deviations and percent bone mineral density in spine (r = 0.588, p = 0.0001; r = 0.374, p = 0.016), respectively. The higher IGF-1 greater percentage bone mineral density. Concentrations of IGF-1 were higher in patients with a history of fracture than non fractured (p = 0.06). A sedentary lifestyle or metabolic disease not significantly correlated with IGF-1 (p › 0.05). No correlation was found between bone mineral density and serum estradiol, found only moderate correlation with IGF-1 (rho = 0.23, p = 0.14). In patients with a history of fracture a significant correlation between estradiol and IGF-1 was found (rho = 0.559, p = 0.05). Conclusions: IGF-1 correlated significantly with age and BMD; with higher IGF-1 greater percentage of bone mineral density. In fractured alone, despite having lower estradiol in relation to the IGF-1; when estradiol rises, IGF-1 increases.


REFERENCES

  1. Raisz L. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. The Journal of Clinical Investigation 2005; 115: 3318-3325.

  2. Programa de Acción para la Prevención y Rehabilitación de Discapacidades Prever-Dis. Programa Nacional de Salud 2001-2006.

  3. Canalis E. Novel treatments for osteoporosis. The Journal of Clinical Investigation 2000; 106: 177-179.

  4. Aguilera M, Guerrero A, Méndez T et al. Effect of dietary calcium versus calcium citrate on conventional biochemical markers in perimenopausal women. Salud Publica Mex 2005; 47: 259-267.

  5. Grundberg E, Carling T, Brändström H, Huang S, Ribom E, Ljunggren Ö et al. A deletion polymorphism in the RIZ gene, a female sex steroid hormone receptor coactivator, exhibits decreased response to estrogen in vitro and associates with low bone mineral density in young swedish women. J Clin Endocrinol Metab 2004; 89: 6173-6178.

  6. Rapuri P, Gallagher J, Haynatzke G. Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women. J Clin Endocrinol Metab 2004; 89: 4954-4962.

  7. Khosla S, Riggs B. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin N Am 2005; 34: 1015-1030.

  8. Fitzpatrick L. Secondary causes of osteoporosis. Mayo Foundation for Medical Education and Research 2002; 77: 453-468.

  9. Livshits G, Pantsulaia I, Trofimov S, Kobyliansky E. Genetic influences on the circulating cytokines involved in osteoclastogenesis. J Med Genet 2004; 41: 76-80.

  10. Delmas P, Pornel B, Felsenberg P, StakkestadJ, Radowicki S et al. Three year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal women. Am J Obstet Gynecol 2001; 184: 32-40.

  11. Ichikawa S, Koller D, Peacock M, Johnson M, Lai D, Hui S et al. Polymorphisms in the estrogen receptor β (ESR2) gene are associated with bone mineral density in caucasian men and women. J Clin Endocrinol Metab 2005; 90: 5921-5927.

  12. Rogers A, Saleh G, Hannon R, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 4470-4475.

  13. Muir M, Romalo G, Wolf L, Elger W, Schweikert H. Estrone sulfate is a major source of local estrogen formation in human bone. J Clin Endocrinol Metab 2004; 89: 4685-4692.

  14. Napoli N, Donepudi S, Sheikh S, Batista G, Armamento VR. Increased 2-hydroxylation of estrogen in women with a family history of osteoporosis. J Clin Endocrinol Metab 2005; 90: 2035-2041.

  15. Lloyd M, Hart D, Nandra D, McAlindon T, Wheeler M, Doyle D et al. Relation between insulin-like growth factor-I concentrations, osteoarthritis, bone density, and fractures in the general population: the Chingford study. Ann Rheum Dis 1996; 55: 870-874.

  16. Vestergaard P, Pernille A, Orskov H, Mosekilde L. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the danish osteoporosis prevention study. J Clin Endocrinol Metab 1999; 84: 2286-2290.

  17. Yakar S, Rosen C, Beamer W, Ackert BC, Wu Y, Liu J et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110: 771-781.

  18. Rivadeneira F, Houwing DJ, Vaerren N, Vergeer DJ et al. Association between an insulin-like growth factor I gene promoter polymorphism and bone mineral density in the elderly: The Rotterdam study. J Clin Endocrinol Metab 2003; 88: 3878-3884.

  19. Yanovski J, Sovik K, Nguyen T, Sebring N. Insulin-like growth factors and bone mineral density in African American and white girls. The Journal of Pediatrics 2000; 137: 826-832.

  20. Kemmler W, Lauber D, Weineck J, Hensen J, Kalender W, Engelke K. Benefits of 2 years of intense exercise on bone density, physical fitness, and blood lipids in early postmenopausal osteopenic women. Arch Intern Med 2004; 164: 1084-1091.

  21. Gourlay M, Brown S. Clinical considerations in premenopausal osteoporosis. Arch Intern Med 2004; 164: 603-614.

  22. Wallace B, Cumming R. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int 2000; 67: 10-11.

  23. Goodman D, Barret E. Epidemiology of insuline like growth factor 1 in elderly men a women. Am J Epidem 1997; 145: 970-976.

  24. Garnero P, Sornay RE, Delmar P. Low serum IGF-1 and ocurrente of osteoporotic fractures in postmenopausal women. Lancet 2000; 355: 898-899.

  25. Dogan E, Posaci C. Monitoring hormone replacement therapy by biochemical markers of bone metabolism in menopausal women. Postgrad Med J 2002; 78: 727-731.

  26. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998; 339: 733-738.

  27. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991; 325: 1189-1195.




2020     |     www.medigraphic.com